肿瘤细胞治疗研究
英文原题：HLA Fully-Mismatched Sibling-Derived CD7 CAR-T Therapy Bridging to Haploidentical Hematopoietic Stem Cell Transplantation for Hepatosplenic γδ T-cell Lymphoma.
然而，由于异基因特性，CAR-T 细胞在达到占循环 T 细胞 83.4% 的峰值后迅速下降。
尽管嵌合抗原受体（CAR）T 细胞疗法治疗 B 细胞淋巴瘤和白血病已显示出显著疗效，但针对 T 细胞恶性肿瘤的研究仍有限。本文报告一例肝脾 γδ T 细胞淋巴瘤患者，该患者对多线化疗耐药，最终接受 HLA 完全不相合的同胞供者来源 CD7 CAR-T 治疗后首次达到完全缓解，流式细胞术确认微小残留病阴性。然而，由于 CAR-T 细胞为异体来源，其在循环 T 细胞中达到 83.4% 的峰值后迅速下降。患者发生细胞因子释放综合征、血细胞减少和感染，但经治疗后均可控制。随后患者接受巩固性单倍体相合造血干细胞移植（HSCT），截至随访结束（CAR-T 输注后 13 个月）仍处于缓解状态。这是首例复发/难治性肝脾 T 细胞淋巴瘤患者接受 HLA 完全不相合同胞来源 CD7 CAR-T 治疗桥接至单倍体相合 HSCT 后获得持久完全缓解的报告。
While chimeric antigen receptor (CAR)-T-cell therapy has demonstrated remarkable effectiveness in the treatment of B-cell lymphomas and leukemias, research on T-cell malignancies is still limited. Here, we reported a patient with hepatosplenic T-cell lymphoma refractory to multiple lines of chemotherapy, who eventually achieved first complete remission with flow cytometry-confirmed minimal residual disease negativity after human leukocyte antigen (HLA) fully-mismatched sibling-derived CD7 CAR-T therapy. However, given the allogeneic nature, CAR-T cells dropped rapidly after a peak of 83.4% of circulating T-cells. Cytokine release syndrome, cytopenia, and infections occurred but were manageable after treatments. After the consolidative haploidentical hematopoietic stem cell transplantation (HSCT), the patient remained in remission at the end of the follow-up (13 months post-CAR-T infusion). This is the first case of relapsed/refractory hepatosplenic T-cell lymphoma who achieved lasting CR after HLA fully-mismatched sibling-derived CD7 CAR-T therapy bridging to haploidentical HSCT.
MEMBER ACCOUNT
登录成功会直接打开下一页。
